Edward Lee Jacobs
Profile
Edward L.
Jacobs was President and Chief Executive officer of Insert Therapeutics, Inc. From 1999 to December, 2006, he held various positions at SuperGen, Inc. From February, 2001 to September, 2001, he was President and Chief Executive Officer of ETEX Corporation.
Prior to that, Mr. Jacobs was Senior Vice President of Commercial Operations for Sequus Pharmaceuticals, Inc. from November, 1997 to March, 1999.
From January, 1995 to November, 1997, he was President and Chief Executive Officer of Trilex Pharmaceuticals Inc. Before that, Mr. Jacobs held various positions such as Chief Executive of Transplant Therapeutics Inc., Vice President and General Manager of Syncor International Inc., Vice President of NEORX Corporation and Business Director of Pharmacia Corp., The Upjohn Company and Johnson & Johnson.
Mr. Jacobs received a BA degree in Political Science and Journalism from California State University.
Former positions of Edward Lee Jacobs
| Companies | Position | End |
|---|---|---|
Insert Therapeutics, Inc.
 Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | President | 29/05/2007 |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Chief Operating Officer | 31/12/2006 |
Apthera, Inc.
 Apthera, Inc. Medical/Nursing ServicesHealth Services Apthera, Inc. develops a pipeline of peptide-based immunotherapies for cancers. It has products in clinical trials aimed at reducing disease recurrence rates for breast, prostate, and pancreatic cancers. The company was founded Robert E. Kennedy, William Gannon, and Joseph Sinkule in July, 2005 and is headquartered in Scottsdale, AZ. | Director/Board Member | - |
Training of Edward Lee Jacobs
| California State University-Northridge | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Insert Therapeutics, Inc.
Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Commercial Services |
Apthera, Inc.
Apthera, Inc. Medical/Nursing ServicesHealth Services Apthera, Inc. develops a pipeline of peptide-based immunotherapies for cancers. It has products in clinical trials aimed at reducing disease recurrence rates for breast, prostate, and pancreatic cancers. The company was founded Robert E. Kennedy, William Gannon, and Joseph Sinkule in July, 2005 and is headquartered in Scottsdale, AZ. | Health Services |
- Stock Market
- Insiders
- Edward Lee Jacobs
